TrialPloS one2017
Safety and pharmacodynamics of dalazatide, a Kv1.3 channel inhibitor, in the treatment of plaque psoriasis: A randomized phase 1b trial.
Eric J Tarcha et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
85 papers cite itlatest 60 shown
this paperpooled itcites it